Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Dendritic Cells Are Defective in Breast Cancer Patients: A Potential Role for Polyamine in This Immunodeficiency
- Dendritic cells DCs are antigen-presenting cells that are currently employed in cancer clinical trials. However, it is not clear whether their ability to induce tumor-specific immune responses when they are isolated from cancer patients is reduced relative to their ability in vivo. The paper determines the phenotype and functional activity...
- White papers 2005-02-25
- Impact of Tetrachloroethylene-Contaminated Drinking Water on the Risk of Breast Cancer: Using a Dose Model to Assess Exposure in a Case-Control Study
- This paper deals in constructing a personal delivered dose PDD model that included personal information on tap water consumption and bathing habits so that inhalation, ingestion, and dermal absorption were also considered. The paper reanalyzes the association between PCE and breast cancer and compared the results to the original RDD...
- White papers 2005-02-25
- Angiogenesis in Male Breast Cancer
- Male breast cancer is a rare but aggressive and devastating disease. This disease presents at a later stage and in a more advanced fashion than its female counterpart. The immunophenotype also appears to be distinct when compared to female breast cancer. Angiogenesis plays a permissive role in the development of...
- White papers 2005-03-02
- A Prospective Study of XRCC1 (X-Ray Cross-Complementing Group 1) Polymorphisms and Breast Cancer Risk
- The gene XRCC1 (X-Ray Repair Cross-Complementing Group 1) encodes a protein involved in DNA base excision repair. Two non-synonymous polymorphisms in XRCC1 (Arg194Trp and Arg399Gln) have been shown to alter DNA repair capacity in some studies in vitro. This paper examines the association between polymorphisms in XRCC1 and breast cancer...
- White papers 2005-11-21
- First-Line Therapy With Gemcitabine and Paclitaxel in Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
- This phase II study evaluated the efficacy and safety of gemcitabine G plus paclitaxel T as first-line therapy in recurrent or metastatic breast cancer. Patients with locally recurrent or metastatic breast cancer and no prior chemotherapy for metastatic disease received G 1200 mg/m2 on days 1 and 8, and T...
- White papers 2005-11-29
- << Previous
- page 1 of 1
- Next >>
